Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651392 | 0.89 | TDP1 (0.46) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL1205124 | 0.88 | HSD17B10 (0.61) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL11085866 | 0.85 | APP (0.36) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL1018438 | 0.84 | HSD17B10 (0.45) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL27472748 | 0.84 | HSD17B10 (0.45) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL27878879 | 0.82 | HSD17B10 (0.45) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL27801149 | 0.80 | HSD17B10 (0.41) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL27637298 | 0.78 | APP (0.40) | HSD17B10KMT2ACYP2C9CYP2C19CYP2D6 | |
| SCHEMBL27801161 | 0.78 | HSD17B10 (0.40) | HSD17B10TDP1KMT2AMEN1CYP2C9 | |
| SCHEMBL6141363 | 0.78 | KDM4E (0.48) | HSD17B10TDP1KMT2AMEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9834538-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-9586929-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2015-10-15 | — | — | US | disclosed |
| US-9096573-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| CN-101952272-B | 6-, 7-or 8-substituted quinazolinone derivatives, compositions containing the same, and methods of use thereof | CELGENE CORP | 2014-08-27 | — | — | CN | disclosed |
| EP-2200999-B1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20130289274-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-10-31 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| CN-101952272-A | 6-, 7-or 8-substituted quinazolinone derivatives, compositions containing the same, and methods of use thereof | CELGENE CORP | 2011-01-19 | — | — | CN | disclosed |
| EP-2200999-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289274-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | HSD17B10 1438/4885TDP1 1051/4885KMT2A 4605/4885 |
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | HSD17B10 1438/4885TDP1 1051/4885KMT2A 4605/4885 |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP2D6, CYP2B6 | HSD17B10 1438/4885TDP1 1051/4885KMT2A 4605/4885 |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | HSD17B10 1438/4885TDP1 1051/4885KMT2A 4605/4885 |
| US-20150291555-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | HSD17B10 1438/4885TDP1 1051/4885KMT2A 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.